AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibuprofen to provide superior pain relief to patients than either agent on its own.
AFT will supply Maxigesic® in NZ and Australia and is looking for a partner to sell the drug overseas. The global pain relief market is worth $27 billion a year and group CEO Dr Hartley Atkinson sees massive potential for this product to take a good share of that.
November 20, 2025
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
November 12, 2025
AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…
September 25, 2025
– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …